ストックスクリーナーアプリを入手
8.07
1.47%
-0.12
前日終値:
$8.19
開ける：
$8.19
24時間の取引高:
598.05K
Relative Volume:
0.55
時価総額：
$830.09M
収益：
-
当期純損益:
$-167.48M
株価収益率:
-4.1385
EPS:
-1.95
ネットキャッシュフロー:
$-197.47M
1週間 パフォーマンス:
-1.94%
1か月 パフォーマンス:
-14.47%
6か月 パフォーマンス:
-43.01%
1年 パフォーマンス:
-51.15%
1日の値動き範囲:
$7.93
$8.29
1週間の範囲:
$7.93
$8.44
52週間の値動き範囲:
$7.88
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
名前
Day One Biopharmaceuticals Inc
セクター
電話
650 484-0899
住所
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
8.07 | 830.09M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-09 | 繰り返されました | Needham | Buy |
| 2024-08-01 | アップグレード | BofA Securities | Underperform → Buy |
| 2024-04-24 | 繰り返されました | Needham | Buy |
| 2023-04-25 | ダウングレード | BofA Securities | Buy → Underperform |
| 2023-02-08 | 開始されました | CapitalOne | Overweight |
| 2023-02-03 | 開始されました | Oppenheimer | Perform |
| 2022-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-12-05 | 開始されました | Goldman | Buy |
| 2022-12-01 | 開始されました | BofA Securities | Buy |
すべてを表示
Day One Biopharmaceuticals Inc (DAWN) 最新ニュース
Swiss National Bank Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Charles Schwab Investment Management Inc. Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Position Boosted by Bank of New York Mellon Corp - Defense World
Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential - TipRanks
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Rhumbline Advisers Has $957,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 5.5% on Analyst Downgrade - Defense World
JPMorgan Chase & Co. Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $34.00 - Defense World
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory - Insider Monkey
HC Wainwright Issues Positive Estimate for DAWN Earnings - MarketBeat
What is Wedbush's Forecast for DAWN Q1 Earnings? - MarketBeat
Research Analysts Offer Predictions for DAWN Q1 Earnings - Defense World
Needham & Company LLC Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
What is Wedbush’s Forecast for DAWN Q1 Earnings? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Quarterly Earnings Results, Misses Estimates By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Misses Expectations By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low After Earnings Miss - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $36.00 Price Target at HC Wainwright - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Wedbush Reiterates “Outperform” Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Earns “Buy” Rating from Needham & Company LLC - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low Following Weak Earnings - Defense World
Day One Biopharma’s Earnings Call Highlights Growth and Challenges - TipRanks
Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Profit Outlook - Simply Wall St
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2024 Earnings Call Transcript - Insider Monkey
Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial - TipRanks
Day One Biopharmaceuticals' (DAWN) Outperform Rating Reiterated at Wedbush - MarketBeat
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth - Investing.com Australia
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals Reports Strong 2024 Results - TipRanks
Adam Dubow Sells 4,646 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock - MarketBeat
Day One Biopharmaceuticals Reports 2024 Financial Results - TipRanks
Day One Biopharmaceuticals, Inc. SEC 10-K Report - TradingView
Earnings Flash (DAWN) Day One Biopharmaceuticals Posts Q4 Revenue $131.2M, vs. FactSet Est of $27.8M - Marketscreener.com
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress - GlobeNewswire
Can Day One's 44% OJEMDA Revenue Surge Accelerate Path to Profitability? - StockTitan
Take off with Day One Biopharmaceuticals Inc (DAWN): Get ready for trading - SETE News
Day One Biopharmaceuticals (DAWN) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Day one biopharmaceuticals’ COO York sells $52,278 in stock By Investing.com - Investing.com Australia
Day one biopharmaceuticals' COO York sells $52,278 in stock By Investing.com - Investing.com South Africa
Day one biopharmaceuticals general counsel sells $55,580 in stock By Investing.com - Investing.com Nigeria
Day One Biopharmaceuticals CEO sells shares for $144,130 By Investing.com - Investing.com Nigeria
Day One Biopharmaceuticals CEO sells shares for $144,130 - Investing.com
Day one biopharmaceuticals' COO York sells $52,278 in stock - Investing.com India
Day one biopharmaceuticals’ COO York sells $52,278 in stock - Investing.com
Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Monday - MarketBeat
TimesSquare Capital Management LLC Has $21.68 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
(DAWN) Trading Advice - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Day One Bio's Talks With FDA Help Secure Glioma Drug Approval - Clinical Leader
Day One Biopharmaceuticals Inc (DAWN) 財務データ
収益
当期純利益
現金流量
EPS
Day One Biopharmaceuticals Inc (DAWN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dubow Adam | GENERAL COUNSEL |
Feb 18 '25 |
Sale |
11.96 |
4,646 |
55,580 |
39,602 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Feb 18 '25 |
Sale |
11.96 |
12,048 |
144,130 |
128,015 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):